Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass A D-D, Wynn DR, Margolin DH, Lake SL, et al. Lancet Neurol. 2011 Apr; 10(4):338-48. PMID: 21397567. Abstract CommentRecommendBookmarkWatch